Eczema (Atopic Dermatitis) Clinical Trials in Worcester

View 31 new treatments for Eczema (Atopic Dermatitis) in Worcester, MA near me. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.
View 30 trials in Worcester
Filter (30)

Transcriptomic Skin Analysis for Atopic Dermatitis

Research Clinic, Boston + 1 more

This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Donald Leung, M.D., Ph.D.
Study Chair

Abrocitinib for Eczema

Research Clinic, Quincy + 1 more

This trial tests abrocitinib, a medication taken regularly, on people with atopic dermatitis who didn't respond well to another treatment or have facial redness. It works by reducing inflammation. Abrocitinib is approved in Europe, the United States, and other countries for the treatment of atopic dermatitis in adults whose disease is not controlled with other treatments.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Robert Bissonnette, MD
Principal Investigator

Dupilumab for Allergic Contact Dermatitis

Research Clinic, Boston + 1 more

The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Ruxolitinib Cream for Atopic Dermatitis/Eczema

Incyte Clinic, Boston + 4 more

This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Skin Cleanser for Eczema

Research Clinic, Boston + 1 more

Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Upadacitinib + Topical Corticosteroids for Eczema

AbbVie Clinic, Boston + 3 more

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

Amlitelimab for Atopic Dermatitis (COAST 2)

Sanofi Clinic, Boston + 2 more

This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, Boston + 3 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Pfizer CT.gov Call Center
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, Brighton + 4 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Upadacitinib for Eczema

AbbVie Clinic, Quincy + 3 more

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Page 1 of 3

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in Worcester, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Worcester is research being conducted for eczema?

Prominent hospitals or neighborhoods in Worcester conducting eczema clinical trials are not explicitly listed. However, trials are actively conducted in various locations, with notable activity in dermatology research centers.

What promising new drugs are being tested?

In Worcester, eczema research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Dupilumab, Tralokinumab, and Upadacitinib.